NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and Bausch + Lomb (NYSE:BLCO – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.
Profitability
This table compares NeuroOne Medical Technologies and Bausch + Lomb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -68.35% | -98.33% | -69.85% |
| Bausch + Lomb | -4.21% | 3.60% | 1.69% |
Institutional and Insider Ownership
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $12.10 million | 2.53 | -$3.61 million | ($0.85) | -4.18 |
| Bausch + Lomb | $5.10 billion | 1.09 | -$360.00 million | ($0.62) | -25.26 |
NeuroOne Medical Technologies has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for NeuroOne Medical Technologies and Bausch + Lomb, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
| Bausch + Lomb | 1 | 9 | 4 | 0 | 2.21 |
NeuroOne Medical Technologies presently has a consensus price target of $11.67, indicating a potential upside of 228.64%. Bausch + Lomb has a consensus price target of $18.08, indicating a potential upside of 15.46%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher possible upside, equities research analysts clearly believe NeuroOne Medical Technologies is more favorable than Bausch + Lomb.
Risk & Volatility
NeuroOne Medical Technologies has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.
Summary
NeuroOne Medical Technologies beats Bausch + Lomb on 8 of the 14 factors compared between the two stocks.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
